Other Stories

Samsung Biologics, AstraZeneca sign strategic manufacturing deal for long-term supply Updated: 2020-09-22 10:06:23 KST

Samsung Biologics and AstraZeneca have announced a long-term global supply agreement.
The deal is valued at nearly 331 million U.S. dollars and will run through 2023.
Samsung's biotech unit will provide the large-scale commercial production of drug substances and drug products to support AstraZeneca's biologics therapeutics.
The contract price could reach almost 550 million dollars based on demand.
It will also allow AstraZeneca to expand its manufacturing capabilities into Asia.
Samsung Biologics has racked up orders worth 1.6 billion dollars so far this year.
Reporter :
KOGL : Korea Open Government License
본 저작물 중 본문에 해당하는 뉴스 스크립트(텍스트)는 공공누리 제1유형-출처표시 조건에 따라 이용할 수 있습니다.